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INTRODUCTION
57
Since the introduction of the first proton pump inhibitor (PPI) omeprazole in the late 1980s, 1 
58
PPIs have generally been considered to be safe and have been widely used in clinical practice. 59
However, with an increasing number of case reports and emerging observational studies on the 60 adverse events in patients receiving long-term PPI therapy, questions about the potential risks 61 associated with their use have recently been raised. Currently, the most prominent concerns 62 about the long-term PPI use relate to the risks of bone fractures, enteric infection, pneumonia 63 and vitamin B 12 deficiency. To a lesser extent, the effects of PPI therapy on the risks of fundic 64 gland polyps (FGPs) and gastric cancer, of which the mechanisms are not well understood, have 65 also drawn attention. 66
Fundic gland polyps are gastric mucosal lesions of small sizes (typically 2-5 mm) located in the 67 fundus or body of the stomach.
2,3 These polyps are composed of cystically dilated fundic glands 68 lined by parietal or chief cells which arrange in a disordered fashion.
4,5 They can be single or 69 multiple, 2,3,5 and be sporadic or associated with an inherited polyposis syndrome such as familial 70 adenomatous polyposis (FAP). 3, 6, 7 In 1992 Graham published a letter noting three cases of FGPs 71 developed after one year of therapy with omeprazole. 8 Since then, case reports describing the 72 occurrence of FGPs in chronic PPI users have steadily emerged over time. [9] [10] [11] [12] [13] [14] [15] However, the 73 association of FGPs with the use of PPIs currently remains a topic of debate and the link 74 between FGPs and the risk of gastric cancer is still unclear. It has been suggested that sporadic 75
FGPs arise through activating mutations of the β-catenin gene, and FAP-associated FGPs are 76 caused by alterations of the somatic adenomatous polyposis coli gene. 16, 17 Although FGPs are 77 generally considered to be benign, some reports showed low-grade dysplasia in FGPs, 18, 19 and 78 one case report describing a chronic PPI user developed FGPs which contained high-grade 79 dysplasia. 20 
80
Several researchers suggest that PPIs cause gastric cancer because they profoundly reduce 81 gastric acid production and consequently lead to increased secretion of gastrin. 82 M A N U S C R I P T
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6 fixed-effect assumption (i.e. all the studies have the same true treatment effect) is valid. 33 The 147 statistical analyses were performed using the R package metaphor. 34 A P-value <0.05 was 148 considered statistically significant. 149
We followed both the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 150 (PRISMA) Statement 35 and the guidelines for Meta-analysis Of Observational Studies in 151
Epidemiology (MOOSE) 36 in reporting this study. 152 Figure 1 shows the flow chart of the selection of studies. The search identified 1,809 studies. 154
RESULTS
153
After screening the titles, abstracts and full text, 12 studies were considered eligible for 155 complete data extraction. Of these, one RCT 37 reported on the effect on gastric polyps (location 156 not specified), six cohort 38-43 and one case-control studies 44 reported on FGPs, and one cohort 45 157 and three case-control studies 46-48 reported on gastric cancer. Table 1 shows characteristics of 158 the included studies, outcomes, characteristics of the drug treatments and study quality (for 159 detailed quality assessment of the observational studies, see Appendix 2). 160
Proton pump inhibitor use and risk of gastric polyps
161
Pooled effect 162
Eight studies (one RCT and seven observational studies) reporting on the effect on FGPs were 163 included in the analysis. Of the observational studies, three studies 40,41,43 adjusted the effect 164 estimates for potential confounding. H. pylori infection status, an important potential 165 confounding factor, was considered in two studies only. 41, 43 The directions of the estimated ORs 166 and their 95% CIs were not consistent among the studies (Figure 2A) Significant heterogeneity was present across studies (P-value <0.0001 (both models); I 2 equalled 170 92.8% and 92.7% in fixed-and random-effects models, respectively). 171 M A N U S C R I P T 
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Publication bias 187
The funnel plot (Figure 4) showed that, out of eight data points, six lay outside the triangle, and 188 six lay on the right side of the triangle altitude. The Egger's regression test of the funnel 189 asymmetry showed highly significant publication bias (P-value <0.0001). 190
Proton pump inhibitor use and risk of gastric cancer
191
Pooled effect 192
Of four included studies reporting on gastric cancer, one case-control study 47 both fixed-and random-effects models ( Figure 2B ). No significant heterogeneity across studies
The sensitivity analysis showed that the direction of the pooled effect of the use of PPIs on 204 gastric cancer and of 95% CI of the pooled effect, and the absence of heterogeneity, were not 205 influenced by any single study in both fixed-and random-effect models (see Appendix 3, Figure 3B) . 212
Publication bias 213
When the number of studies is small, the visual interpretation and test for asymmetry of the 214 funnel plot of the publications are not reliable. 30 With three included studies reporting on 215 gastric cancer, we did not assess the bias of these publications. 216
DISCUSSION
217
Proton pump inhibitor use and risk of gastric polyps
218
The summary effect and its 95% CI based on the estimates from one RCT and seven 219 observational studies showed that the use of PPIs was associated with an increased risk of FGPs. 220
The likelihood of this association was strengthened by the fact that the pooled OR and its lower 221 bound of the 95% CI from studies with higher quality were much larger than those from studies 222 with lower quality and from all studies. However, the magnitude of the mean effect size remains 223 unclear. Of the eight included studies, only three 40,41,43 adjusted the effect estimates for 224 potential confounders. The development of FGPs is known to be suppressed by H. pylori. [49] [50] [51] 225 However, the status of H. pylori infection was considered for adjustment only in two studies. 41, 43 226 Duration of PPI use is an important factor influencing the risk of FGPs, 40 but is not specifically 227 reported in most of the studies. In general, there was diversity in the PPI exposure. Mean 228 (range) of duration of PPI use was 37.4 (3-98) months in the study by Choudhry et al. 38 and was 229 21.9 (1-97) months in study by Hsu et al. 42 In other studies, mean or median duration of PPI use 230
was not reported and the duration ranges varied widely from 5 to >48 months. In all the 231 included studies, FGPs were found in patients undergoing an esophagogastroduodenoscopyM A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
PPIs in these patients might be confounded by indication, because the patients with GERD are 234 often prescribed PPIs and might have a higher risk of FGPs. 52 Because none of the included 235 studies adjusted the effect estimates for a history or presence of GERD, their findings might be 236
biased. 237
The sensitivity analysis showed that the study by Vieth and Stolte 39 had a considerable impact 238 on the pooled effect from the fixed-effect model; this is in agreement with the observation that 239 this study 39 had a weight far larger than those of other studies, and its effect estimate was 240 smallest among all studies except one (see Figure 2A ). However, since the exclusion of the study 241
by Vieth and Stolte 39 did not change the direction of the 95% CI of the pooled effect from any of 242 the models, the likelihood of the association between PPI use and the risk of FGPs was not 243 influenced by this study. 39 
244
Because of the presence of a considerable heterogeneity across the included studies, the 245 assumption in the fixed-effect model that the true effect is the same value in every study may 246 not hold. 30 Despite this, the pooled ORs and the 95% CIs obtained from both fixed-and random-247 effects models consistently showed that the use of PPIs was associated with an increased risk of 248
FGPs. 249
The results from the analysis of the subgroups by length of PPI exposure suggest that the risk of 250
FGPs increases with increasing duration of PPI use. This subgroup analysis suggests that the use 251 of PPI for at least 12 months is a necessary condition for the development of FGPs. This 252 observation is in line with the results from several studies published in the form of abstract or 253 letter, which showed an increased risk of FGPs in patients receiving PPIs for 12 months or 254 longer.
53-56 255
Despite the finding that the use of PPIs was associated with an increased risk of FGPs, the 256 clinical significance of PPI-associated FGPs remains unclear. Benign gastric polyps have been 257 found incidentally in 5 to 140 out of 1000 people undergoing an EGD, 18,57,58 and 3-77% of these 258 gastric polyps could be FGPs. 18, 41, [57] [58] [59] In the study by Choudhry et al., 38 no hyperplasia or 259 dysplasia was found in the FGPs in seven PPI users. In the study by Jalving et al., 40 one and seven 260 patients among 19 patients with FAP-associated FGPs had high-and low-grade dysplasia in 261
FGPs, respectively; among these eight patients with dysplasia, only two patients used PPIs.development of FGPs and/or dysplasia in FGPs in FAP patients was unlikely to be related to PPIM A N U S C R I P T
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use. In contrast, in two studies published in abstract form, Weinstein and colleagues noted that 265 the use of omeprazole increased hyperplasia in the mucosa adjacent to the FGPs, 60 and Hirt and 266 colleagues suggested that FGPs associated with PPI use exhibited a histologic difference from 267 the sporadic FGPs that were traditionally described. 61 In another study, among patients with 268 FAP-associated FGPs, two patients were on long-term PPI therapy (>6 months) and both had 269 dysplasia; in comparison, only three out of seven patients not receiving PPIs had dysplasia. 62 
270
Apart from these observations, there has been no large, systematic study on the association 271 between the PPI-related FGPs and the development of dysplasia or carcinoma. 272
Proton pump inhibitor use and risk of gastric cancer
273
The summary effect and its 95% CI based on the estimates from three observational studies 274
suggest that the use of PPIs may be associated with an increased risk of gastric cancer. This is in 275 agreement with the results from the study by Ahn et al., 63 which examined the association 276 between the use of acid suppressive drugs, including histamine H 2 receptor antagonists (H 2 RA) 277
and PPIs, and the risk of gastric cancer. In their meta-analysis, the authors of this study 63 63 the messages are the same at the first glance. However, the 281 magnitude and the statistical significance of the association between PPI use and the risk of 282 gastric cancer remain uncertain. In the study by Ahn et al. 63 the potentially biased outcomes 283 from the included studies were briefly mentioned, but various sources of bias and uncertainty in 284 the summary effect of PPIs were not discussed in great details. From the included studies, only 285 four values of RRs were available for the meta-analysis, of which two RRs were not significantly 286 different from 1. Helicobacter pylori infection is a major confounding factor, because it is 287 associated with both PPI prescription and risk of gastric cancer. The study by Poulsen et al. Other potential confounding factors include early symptoms of gastric cancer similar to benign 292 gastric conditions like GERD and peptic ulcers, which can lead to PPI prescriptions. Except for 293 the study by Garcia Rodriguez et al., 46 which adjusted the effect estimates for a history of GERD, 294 peptic ulcer and dyspepsia, none of the included studies attempted to reduce this potentialM A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 11 bias. Diet (e.g. smoked foods or cured meats), inherited cancer syndromes and family history of 296 gastric cancer are among other potential confounders, but none of them were considered in the 297 included studies. 298
To the best of our knowledge, no meta-analyses of studies examining the association between 299 PPI therapy and gastric cancer, except for those in the study by Ahn et al. 63 and our study, have 300 been carried out. In our study, a subgroup analysis of the effect of PPIs with regard to the 301 duration of therapy was performed. This added new information to the existing literature, 302 because in the study by Ahn et al. 63 no such an analysis directed specifically at the PPI use was 303 conducted. Our analysis showed that the pooled RR, and the lower and upper bounds of its 95% 304 CI in patients using PPI for less than 12 months were larger than those in patients using PPI for 305 12 months or longer, but smaller than those in patients using PPI for more than 36 months. >36 months) were small, which made the estimates of the summary RRs imprecise. 328
Study strengths and limitations
329
In this review, the quality of the included studies, including the bias in their results, were 330 rigorously assessed. We used both fixed-and random-effects model to summarize the effects 331 of PPI use on the risk of gastric polyps and cancer, and compared the results from two types of 332 models. 333
Our study has some limitations. The number of included studies reporting on gastric cancer was 334 small and thus the pooled effects and the heterogeneity assessment may be imprecise, and the 335 publication bias of these studies could not be adequately assessed. 30 Because the status of H. 336 pylori infection was only partially controlled for in one study, we could not distinguish between 337 an isolated PPI effect and a synergistic PPI-H. pylori effect. In the subgroup analysis, we did not inhibitors. CC, case-control study; CH, cohort study; FGPs, fundic gland polyps; GC, gastric 531 cancer; GCA, gastric cardia adenocarcinoma; GNCA, gastric non-cardia adenocarcinoma; GPs, 532 gastric polyps; RCT, randomised controlled trial. 533 Figure 3 . Forest plots of (A) odds ratios for fundic gland polyps and (B) risk ratios of gastric 534 cancer in subgroups of patients receiving proton pump inhibitors for different durations 535 compared with subjects not receiving proton pump inhibitors. FGPs, fundic gland polyps; GC, 536 gastric cancer; GCA, gastric cardia adenocarcinoma; GNCA, gastric non-cardia adenocarcinoma; 537 PPI, proton pump inhibitor. 538 
